Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 5, 2013, Pages 574-580

  Norris, Virginia ^a   Ambery, Claire ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bi functional molecule; Bronchodilatory effects; COPD; Dual pharmacophore; GSK961081; Ipratropium bromide; MABA; Salbutamol

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; FLUTICASONE PROPIONATE; GLUCOSE; GSK 61081; IPRATROPIUM BROMIDE; PLACEBO; POTASSIUM; SALBUTAMOL; SALMETEROL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; DYSGEUSIA; FEMALE; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; HYPOKALEMIA; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; PAIN; PHARMACODYNAMICS; PHARMACOPHORE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREMOR; UPPER ABDOMINAL PAIN;

BI-FUNCTIONAL MOLECULE; BRONCHODILATORY EFFECTS; COPD; DUAL PHARMACOPHORE; GSK961081; IPRATROPIUM BROMIDE; MABA; SALBUTAMOL;

AGED; ALBUTEROL; BRONCHODILATOR AGENTS; CARBAMATES; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84882601233     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.03.009     Document Type: Article

References (20)

1. The global initiative for chronic obstructive lung disease (GOLD) revised 2011; http://www.goldcopd.com.
2. Celli B.R., MacNee W., Agusti A., Anzueto A., Berg B., Buist A.S., et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
3. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Verhaert J., Disse B., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005, 26:214-222.
4. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Zaagsma J., Mueller A., et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med 2010, 104:995-1004.
5. van Noord J.A., Aumann J.L., Janssens E., Verhaert J., Smeets J.J., Mueller A., et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129:509-517.
6. Terzano C., Petroianni A., Conti V., Ceccarelli D., Graziani E., Sanduzzi A., et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med 2008, 102:1701-1707.
7. van Noord J.A., Buhl R., LaForce C., Martin C., Jones F., Dolker M., et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010, 65:1086-1091.
8. 2-agonist molecules for the treatment of chronic obstructive pulmonary disease. Future Med Chem 2011, 3:1585-1605.
9. Aiyar J., Steinfeld T., Pulido-Rios M.T., Chin K., Lee T.W., Jasper J., et al. Characterization of TD-5959: a novel bifunctional molecule with muscarinic antagonist and beta2-adrenergic agonist activity. Am J Respir Crit Care Med 2009, 179:A4552.
10. Pulido-Rios M.T., McNamara A., Kwan K., Martin W., Thomas R., Mammen M., et al. TD-5959: a novel bifunctional muscarinic antagonist - b2-adrenergic agonist with potent and sustained invivo bronchodilator activity in guinea pigs. Am J Respir Crit Care Med 2009, 179:A6195.
11. Norris V., Zhu C., Ambery C., Norris V. The pharmacodynamics of GSK961081 in patients with COPD 2011, European Respiratory Society meeting, Amsterdam, Abstract number 823.
12. Wielders P.L., Ludwig-Sengpiel A., Locantore N., Baggen S., Chan R., Riley J.H. Adual-acting muscarinic antagonist, β2-agonist [MABA] molecule (GSK961081) improves lung function in COPD. A randomised trial 2012, European Respiratory Society meeting, Vienna, Abstract number 3081.
13. Cazzola M., Santus P., D'Adda A., Pizzolato S., Di Marco F., Centanni S. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD. Pulm Pharmacol Ther 2009, 22:177-182.
14. Cazzola M., Di Perna F., Noschese P., Vinciguerra A., Calderaro F., Girbino G., et al. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. Eur Respir J 1998, 11:1337-1341.
15. Kerstjens H.A., Bantje T.A., Luursema P.B., Sinninghe Damste H.E., de Jong J.W., Lee A., et al. Effects of short-acting bronchodilators added to maintenance tiotropium therapy. Chest 2007, 132:1493-1499.
16. Goldkorn A., Diotto P., Burgess C., Weatherall M., Holt S., Beasley R., et al. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol. Respirology 2004, 9:102-108.
17. Rosenkranz B., Rouzier R., Kruse M., Dobson C., Ayre G., Horowitz A., et al. Safety and tolerability of high-dose formoterol (via aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. Respir Med 2006, 100:666-672.
18. 2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device. Br J Clin Pharmacol 1993, 36:445-450.
19. Bennett J.A., Tattersfield A.E. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax 1997, 52:458-464.
20. Fabbri L.M., Luppi F., Beghe B., Rabe K.F. Complex chronic comorbidities of COPD. Eur Respir J 2008, 31:204-212.